7 research outputs found
Dose response curves for cenicriviroc-dependent inhibition (A) and maraviroc-dependent inhibition (B).
<p>R5, dual and X4-tropic HIV-2 strains are depicted in continuous, dashed and dotted black lines, respectively. HIV-1 R5-tropic strain is depicted using the continuous gray line.</p
HIV serological and molecular testing for dually HIV-1 and HIV-2 diagnosis in West Africa.
HIV serological and molecular testing for dually HIV-1 and HIV-2 diagnosis in West Africa.</p
Demographic characteristics of participants according to initial HIV status based on national HIV testing algorithms in West Africa.
Demographic characteristics of participants according to initial HIV status based on national HIV testing algorithms in West Africa.</p
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants - Fig 2
<p><b>Comparison of the quantification of minority resistant variants (MRV) using SmartGene<sup>®</sup> (SG) and Geneious<sup>®</sup> pipeline analysis for protease mutations (A, B), Reverse Transcriptase (RT) (C, D) and integrase mutations (E, F).</b> Minority resistant variants frequencies were depicted according to linear regression (A, C, E) and Bland-Altman (B, D, F) analyses. For Bland-Altman analysis, y-axis indicates the percentage of difference in MRV frequency measurements between Geneouis<sup>®</sup> and SG<sup>®</sup> analysis and x-axis indicates the mean of the two measurements. All MRV detected by both software were included in this analysis. The 95% confidence interval limits of agreement were calculated. Mean, upper and lower limits of agreement were depicted by the dotted lines.</p
AVA<sup>®</sup> and SmartGene<sup>®</sup> analyses.
<p>AVA<sup>®</sup> and SmartGene<sup>®</sup> analyses.</p
Geneious<sup>®</sup> and SmartGene<sup>®</sup> analyses.
<p>Geneious<sup>®</sup> and SmartGene<sup>®</sup> analyses.</p
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants - Fig 1
<p><b>Comparison of the quantification of minority resistant variants (MRV) using SmartGene<sup>®</sup> (SG) and AVA<sup>®</sup> pipeline analysis for protease mutations (A,B) and Reverse Transcriptase (RT) (C, D) mutations after excluding two major discrepancies</b>. Minority resistant variants frequencies were depicted according to linear regression (A, C) and Bland-Altman (B, D) analyses. For Bland-Altman analysis, y-axis indicates the percentage of difference in MRV frequency measurements between AVA<sup>®</sup> and SG<sup>®</sup> analysis and x-axis indicates the mean of the two measurements. All MRV detected by both software were included in this analysis. The 95% confidence intervals limits of agreement were calculated. Mean, upper and lower limits of agreement were depicted by the dotted lines.</p